GSK plc
GLAXF- Exchange
- OTC
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001131399
No open-market purchases or sales by GSK plc insiders were filed in the last 90 days; 2 institutions reported holding it in 13F filings for Q2 2026, worth $70.1M in total; no superinvestor holds it.
Other share classesGSK
Key figures
- Insider buysOpen market, last 90 days
- 0
- Insider sellsOpen market, last 90 days
- 0
- 13F holdersQ2 2026, 0 vs. previous quarter
- 2
- 13F valueReported value at the end of Q2 2026
- $70.1M
- Superinvestors holdingAt the end of Q2 2026
- 0
Price chart
Superinvestors holding GLAXF, Q2 2026
No superinvestor reported holding GLAXF at the end of Q2 2026.
Latest insider trades
Open-market purchases and sales by GSK plc insiders from Form 4, newest first.
No open-market purchases or sales by GSK plc insiders are on file.
Top 10 13F holders, Q2 2026
The largest institutional positions in GSK plc at the end of Q2 2026; share changes are against Q1 2026.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Aristotle Capital Management, LLC | 2,633,914 | $69.3M | 0.15% | −190,807−6.8% | Reduced |
| Generali Investments CEE, investicni spolecnost, a.s. | 34,105 | $895.8K | 0.04% | −4,209−11.0% | Reduced |